How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). Dillon R, Potter N, Freeman S, Russell N, et al. Br J Haematol 2021;193:231-244.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dillon R, Potter N, Freeman S, Russell N, et al. How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML). Br J Haematol 2021;193:231-244.
PMID: 33058194